DKK1 as a novel target for myeloma immunotherapy

 Abstract

Novel, potent tumor-associated antigens are needed to improve the efficacy of immunotherapy for myeloma. We demonstrated that active vaccination using the DKK1-DNA vaccine in the myeloma mouse model protected mice from developing myeloma and effectively treated established myeloma. Therefore, DKK1 could be developed as a novel vaccine for myeloma immunotherapy.

Full Text Options
Article
Metrics
 Share
 Full Text
 Info
Pages
756 - 758
doi
10.4161/onci.19655
Type
Author's View
 Metrics
 Cite This Article
 Permissions
Creative Commons License Permissions
 Reprints
DKK1 as a novel target for myeloma immunotherapy